Clinical Trials /

Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)

NCT03167619

Description:

This is a randomized, international, multicenter, Phase II study designed to explore the efficacy of olaparib or olaparib in combination with durvalumab in platinum-treated mTNBC. The primary objectives are to explore olaparib or olaparib in combination with durvalumab as maintenance therapy following clinical benefit with platinum-based therapy in subjects with mTNBC.

Related Conditions:
  • Breast Carcinoma
Recruiting Status:

Recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)
  • Official Title: Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer

Clinical Trial IDs

  • ORG STUDY ID: Pro00080769
  • NCT ID: NCT03167619

Conditions

  • Triple Negative Breast Cancer

Interventions

DrugSynonymsArms
Olaparib Oral ProductA - olaparib alone
Olaparib Oral Product in combination with DurvalumabB - olaparib plus durvalumab

Purpose

This is a randomized, international, multicenter, Phase II study designed to explore the efficacy of olaparib or olaparib in combination with durvalumab in platinum-treated mTNBC. The primary objectives are to explore olaparib or olaparib in combination with durvalumab as maintenance therapy following clinical benefit with platinum-based therapy in subjects with mTNBC.

Detailed Description

      Subjects suitable for enrollment into this trial are adult subjects with histologically
      documented triple negative adenocarcinoma of the breast that is inoperable, locally advanced,
      or metastatic, and is not amenable to resection with curative intent, and who have received
      at least 4 cycles of platinum-based chemotherapy in the 1st or 2nd line setting AND derived
      clinical benefit (CR / PR / SD) per RECIST 1.1 with platinum-based therapy as determined by
      the treating physician.

      Eligible subjects will be randomized to either olaparib or olaparib in combination with
      durvalumab. Study treatment will continue until disease progression, intolerable toxicity,
      elective withdrawal from the study, or study completion or termination. Upon treatment
      discontinuation, subjects will be followed every 2 months for survival.

      Although randomization will be used to allocate subjects to either the olaparib or olaparib
      in combination with durvalumab arm, no comparisons between treatment regimens are planned.
      The purpose of randomization was to reduce bias due to subject selection into either
      treatment arm.
    

Trial Arms

NameTypeDescriptionInterventions
A - olaparib aloneExperimentalTwice daily oral Olaparib 300mg alone as maintenance therapy until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
  • Olaparib Oral Product
B - olaparib plus durvalumabExperimentalTwice daily oral olaparib plus intravenous Durvalumab every 4 weeks as maintenance therapy until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
  • Olaparib Oral Product in combination with Durvalumab

Eligibility Criteria

        Inclusion Criteria:

          1. Age ≥ 21 years of age

          2. ECOG performance status 0-2

          3. Inoperable locally advanced or metastatic breast cancer not amenable to resection with
             curative intent and histologically confirmed to be estrogen receptor (ER) negative,
             progesterone receptor (PR) negative, and HER2 negative:

               -  ER status is defined as ≤ 10% tumor cells positive for ER by immunohistochemistry
                  (IHC), irrespective of staining intensity

               -  PR status is defined as ≤ 10% tumor cells positive for PR by IHC, irrespective of
                  staining intensity

               -  HER2 negative status is determined by:

               -  IHC 1+, as defined by incomplete membrane staining that is faint/barely
                  perceptible and within > 10% of invasive tumor cells, or

               -  IHC 0, as defined by no staining observed or membrane staining that is incomplete
                  and is faint/barely perceptible and within ≤ 10% of the invasive tumor cells, or

               -  FISH negative based on:

               -  Single-probe average HER2 copy number < 4.0 signals / cell, or

               -  Dual-probe HER2/CEP17 ratio < 2.0 with an average HER2 copy number < 4.0 signals
                  / cell

          4. Minimum six 1-weekly doses or three 3-weekly doses of platinum chemotherapy
             (monotherapy or combination therapy at investigator's discretion) with stable disease
             (SD), partial response (PR) or complete response (CR) to the platinum therapy as
             assessed by investigator.

          5. Has received no more than 2 prior chemotherapy regimens for metastatic breast cancer
             including current platinum based chemotherapy.

          6. Able to provide a representative formalin-fixed, paraffin embedded tumour specimen
             archival or fresh tissue for correlative studies and biomarker analysis.

          7. Hemoglobin ≥ 9.0 g/dL and no blood transfusions in the 28 days prior to study entry.
             Absolute neutrophil count ≥1,500/mm3. Platelet count ≥100 x 10^9/L.

          8. Total bilirubin <1.5 x the upper limit of normal (ULN) with the following exception:
             subjects with known Gilbert's disease who have serum bilirubin <3 x ULN may be
             enrolled.

          9. Aspartate transaminase (AST) and alanine transaminase (ALT) <2.5 x ULN with the
             following exceptions: subjects with documented liver or bone metastases may have AST
             and ALT <5 x ULN.

         10. Alkaline phosphatase (ALP) <2 x ULN (<5 x ULN in subjects with known liver involvement
             and <7 ULN in subjects with known bone involvement).

         11. Serum creatinine <1.5 x ULN or creatinine clearance >51 mL/min by the Cockcroft-Gault
             formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of
             creatinine clearance.

         12. For subjects of childbearing potential, agreement (by both subject and partner) to use
             two effective forms of contraception, including surgical sterilization, reliable
             barrier method, birth control pills, contraceptive hormone implants, or true
             abstinence and to continue its use for the duration of the study and for 3 months
             after last dose of study treatment.

         13. Subjects of childbearing potential should have a negative urine or serum pregnancy
             test during their screening visit. If the urine test is positive or cannot be
             confirmed as negative, a serum pregnancy test will be required.

         14. Subjects willing and able to comply with the protocol for the duration of the study
             including undergoing treatment and scheduled visits and examination.

         15. For inclusion in genetic research, subjects must provide informed consent for genetic
             research collection of specimens to be stored at repository for future research.

        Exclusion Criteria:

          1. Currently participating and receiving study therapy or has participated in a study of
             an investigational agent and received study therapy or used an investigation device
             within 4 weeks of first dose of treatment. Subjects who have entered the follow-up
             phase of an investigational study may participate as long as it has been 4 weeks since
             last dose of the previous investigational agent or device.

          2. Concurrent enrollment in another clinical study, unless it is an observational (non
             interventional) clinical study or the follow-up period of an interventional study.

          3. Active autoimmune disease that has required systemic treatment in past 2 years (ie,
             with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
             Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement
             therapy for adrenal or pituitary insufficiency, or similar treatment) is not
             considered a form of systemic treatment.

          4. Is taking chronic systemic steroids in doses > 10mg of prednisolone or equivalent
             within 7 days prior to the first dose of trial treatment.

          5. Previous treatment with PARP inhibitors including olaparib.

          6. Received prior therapy with an anti-PD-1, anti-PD-L1 (including durvalumab) or an
             anti-PD-L2 agent.

          7. Known active central nervous system metastasis and / or carcinomatous meningitis.
             Subjects with previously treated brain metastases may participate, provided they have:

               1. Stable brain metastases [without evidence of progression by imaging (confirmed by
                  computerized tomography {CT} scan if CT used at prior imaging) for at least four
                  weeks prior to the first dose of trial treatment**,

               2. No evidence of new or enlarging brain metastases; any neurologic symptoms should
                  have returned to baseline,

               3. Not used steroids for brain metastases in the 7 days prior to trial initiation.
                  Taking chronic systemic steroids in doses ≤ 10mg of prednisolone is allowed.

                    -  This exception does not include carcinomatous meningitis, as subjects with
                       carcinomatous meningitis are excluded regardless of clinical stability.

          8. History and/or confirmed pneumonitis, or extensive bilateral lung disease on high
             resolution/spiral CT scan.

          9. Patients with suspected or confirmed myelodysplastic syndrome/acute myeloid leukemia.

         10. History of another primary malignancy except for:

               1. Malignancy treated with curative intent and with no known active disease ≥5 years
                  before the first dose of study drug and of low potential risk for recurrence.

               2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
                  of disease.

               3. Adequately treated carcinoma in situ without evidence of disease eg, cervical
                  cancer in situ.

         11. Major surgery within 2 weeks of starting the study, and subjects must have recovered
             from any effects of any major surgery.

         12. Receipt of radiation therapy within 4 weeks prior to starting study drug(s). Limited
             field of radiation for palliation within 2 weeks of the first dose of study treatment
             is allowed provided:

               1. The lung is not in the radiation field

               2. Irradiated lesion(s) cannot be used as target lesions

         13. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable
             angina pectoris, cardiac arrhythmia, active peptic ulcer disease, active bleeding
             diatheses including any subjects known to have evidence of acute or chronic hepatitis
             B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness / social
             situations that would limit compliance with study requirements or compromise the
             ability of the subject to give written informed consent.

         14. Subjects unable to swallow orally administered medication, and subjects with
             gastrointestinal disorders likely to interfere with absorption of the study
             medication.

         15. Subjects requiring treatment with potent inhibitors or inducers of CYP3A4.

         16. Pregnant or breast-feeding women. If breastfeeding can be stopped prior to study
             enrollment until 1 month after the last study dose, then the patient could be allowed
             to enter the study.

         17. Immunodeficient subjects, eg, subjects who are known to be serologically positive for
             human immunodeficiency virus (HIV).

         18. Received a live vaccine within 30 days of planned start of study therapy.

         19. Subjects with a known hypersensitivity to olaparib or durvalumab, or any of the
             excipients of the product.

         20. Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative
             colitis)

         21. History of allogeneic organ transplant

         22. Active bleeding diatheses

         23. Patients with known active hepatic disease (ie, Hepatitis B or C)

         24. Known history of previous clinical diagnosis of tuberculosis.
      
Maximum Eligible Age:N/A
Minimum Eligible Age:21 Years
Eligible Gender:Female
Healthy Volunteers:No

Primary Outcome Measures

Measure:Efficacy as assessed by PFS
Time Frame:From date of randomization until the date of documented progression or date of death, whichever came first, approximately 1 year.
Safety Issue:
Description:To determine the efficacy as assessed by PFS of maintenance olaparib or olaparib in combination with durvalumab following clinical benefit (complete response [CR], partial response [PR] or stable disease [SD]) with platinum based chemotherapy in the 1st or 2nd line setting for treatment of metastatic triple negative breast cancer (mTNBC).

Secondary Outcome Measures

Measure:Overall Survival Olaparib alone
Time Frame:study duration, approximately 2 years
Safety Issue:
Description:To determine the efficacy of maintenance olaparib following platinum based chemotherapy as assessed by overall survival (OS).
Measure:Overall Survival olaparib in combination with Durvalumab
Time Frame:study duration, approximately 2 years
Safety Issue:
Description:To determine the efficacy of maintenance olaparib in combination with durvalumab following platinum based chemotherapy as assessed by overall survival (OS).
Measure:Determine safety and tolerability as determined by adverse events of maintenance olaparib alone.
Time Frame:through study completion, approximately 1 year
Safety Issue:
Description:Determine safety and tolerability of maintenance olaparib following platinum based chemotherapy.
Measure:Determine safety and tolerability as determined by adverse events of maintenance olaparib plus durvalumab
Time Frame:through study completion, approximately 1 year
Safety Issue:
Description:Determine safety and tolerability of maintenance olaparib in combination with durvalumab following platinum based chemotherapy.
Measure:Olaparib alone overall response rate (ORR)
Time Frame:through study completion, approximately 1 year
Safety Issue:
Description:To determine the efficacy of maintenance olaparib following platinum-based chemotherapy as assessed by overall response rate (ORR).
Measure:Olaparib in combination with Durvalumab overall response rate (ORR)
Time Frame:through study completion, approximately 1 year
Safety Issue:
Description:To determine the efficacy of maintenance olaparib in combination with durvalumab following platinum-based chemotherapy as assessed by overall response rate (ORR).

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Duke University

Trial Keywords

  • Mestastic
  • Platinum Sensitive
  • Advanced
  • PARP inhibitor

Last Updated